Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06654024
Starting soon Observational

Urinary Congophilia as an Indicator of Activity of Lupus Nephritis

NCT06654024 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2024-12
Last updated
2024-12-16

Condition(s) studied

Lupus Nephritis (LN)

Study summary

Evaluation of the impact of SLE on urinary levels of congophilia and their relationship to renal histopathology and activity of lupus nephritis (LN)

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: \- Adult patients ≥ 18 years old that were diagnosed with SLE according to EULAR/ACR classification criteria 2019 for SLE, and lupus nephritis based on renal biopsy or active urinary sediment (proteinuria or hematuria ) Exclusion Criteria: * Any patient has evidence of nephritis that may cause proteinuria as diabetes mellitus and any other causes of glomerulonephritis other than lupus nephritis * pregnant females with lupus nephritis and hypertensive disorders

Primary outcome measure(s)

  • urinary congophilia level in patient with lupus nephritis is a marker for disease activity — baseline
    Urinary congophilia levels increase in patients with lupus nephritis so that it can be used as a non-invasive urinary marker of lupus nephritis activity.

Trial sites (1)

FacilityCityRegionStatus
Assuit University ,Faculty of Medicine Assute Assute

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon

Other trials for the same condition

The Role of Transforming Growth Factor- Beta (TGF- β) Expression in Renal Biopsy of Lupus Nephritis Patients Active, not recruiting
The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population Recruiting
Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06654024 on ClinicalTrials.gov ↗ ← All trials in Egypt